From the Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
ASST Pavia, Viale Repubblica, Pavia, Italy.
J Clin Psychopharmacol. 2023;43(2):157-160. doi: 10.1097/JCP.0000000000001662.
Clozapine represents the criterion standard therapy for patients with treatment-resistant schizophrenia. Unfortunately, a significant percentage of such patients are also partial responders to clozapine. Consequently, several augmentation strategies have been proposed with various and sometimes controversial efficacy. Among these add-on treatments, lurasidone has been recently introduced and could represent a potential option, especially for the additional positive effect on cognitive symptoms.
This case series aims to determine possible advantages of lurasidone augmentation in four patients treated with clozapine, who were diagnosed with treatment-resistant schizophrenia. Positive and Negative Syndrome Scales were used to evaluate psychopathology, the Udvalg for Kliniske Undersøgelser scale for tolerability and safety.
All patients achieved a significant reduction of both positive and negative symptoms, with no significant adverse effects to be reported.
Our observation suggests that lurasidone can lead to clinically significant improvements in psychopathology with a good tolerability profile when added to clozapine.
氯氮平是治疗抗药性精神分裂症患者的标准治疗方法。不幸的是，相当一部分此类患者对氯氮平也只是部分反应。因此，已经提出了几种增效策略，其疗效各不相同，有时甚至存在争议。在这些附加治疗中，鲁拉西酮最近被引入，可能是一种潜在的选择，尤其是对认知症状有额外的积极影响。
本病例系列旨在确定在 4 名接受氯氮平治疗的被诊断为抗药性精神分裂症患者中，鲁拉西酮增效治疗的可能优势。使用阳性和阴性综合征量表评估精神病理学，使用 Udvalg for Kliniske Undersøgelser 量表评估耐受性和安全性。
所有患者的阳性和阴性症状均显著减轻，无明显不良反应报告。
我们的观察结果表明，当添加到氯氮平时，鲁拉西酮可导致精神病理学方面的临床显著改善，具有良好的耐受性。
